Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function

Abstract

A cDNA for human topoisomerase I (Topo 1) was used to identify a 4.1 kb polyadenylated Topo 1 mRNA in methotrexate-resistant human KB cells that are permissive for herpes simplex virus type 2 (HSV-2) infection. Using these cells, no effect of the HSV-2-associated early shut-off function on levels of Topo-1 mRNA was observed up to 6 hours postinfection, whereas the actin mRNA level was 22% cellular transcripts are susceptible. The level of several host-cell polyadenylated RNAs detected as cDNA clones (class 3 transcripts) were unchanged 8 hours after HSV-2 infection, and other cellular transcripts (class 2) actually accumulated at postinfection.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bastow, K.F., Bouchard, J., Ren, X.-J. and Cheng, Y.-C., Virol149, 199–207, 1986.

  2. 2.

    Fenwick, M.C. and McMenamin, M.M., J Gen Virol65, 1225–1228, 1984.

  3. 3.

    Hill, T.M., Sadler, R.J. and Betz, J.L., J Virol56, 312–316, 1985.

  4. 4.

    Inglis, S.C., Mol Cell Biol2, 1644–1648, 1982.

  5. 5.

    Morse, L.S., Pereira, L., Roizman, B. and Schaffer, P.A., J Virol26 389–410, 1978.

  6. 6.

    Read, G.S. and Frenkel, N., J Virol46, 495–512, 1983.

  7. 7.

    Shek, N. and Bachenheimer, S.L., J. Virol55, 601–610, 1985.

  8. 8.

    Kemp, L.M., Brickell, P.M., La Thangue, N.B. and Latchman, D.S., Bioscience Reports6, 945–951, 1986.

  9. 9.

    Latchman, D.S., Estridge, J.K. and Kemp, L.M., Nucl Acids Res15, 7283–7293, 1987.

  10. 10.

    Chang, A.C.Y., Nunberg, J.H., Kaufman, R.J., Erlich, H.A., Schimber, R.T. and Cohen, E.S.N., Nature (London)275, 617–624, 1978.

  11. 11.

    Han, F.-S., Dutschman, G.E., Huang, Y.S. and Cheng, Y.-C., Proc Ann Meet Amer Assoc Cancer Res26, 10, 1985.

  12. 12.

    Rose, K.M., Szopa, J., Han, F.-S., Cheng, Y.-C., Richter, A. and Scheer, U., Chromosoma,96, 411–416, 1988.

  13. 13.

    D'Arpa, P., Machlin, P.S., Ratrie, H., Rothfield, N.F., Cleveland, D.W. and Earnshaw, W.C., Proc Natl Acad Sci USA85, 2543–2547, 1988.

  14. 14.

    Bastow, K.F., Prabhu, R. and Cheng, Y.-C.. in Weber, G (ed.)Advances in Enzyme Regulation, Vol. 22. Pergamon Press, New York, 1984, pp. 15–26.

  15. 15.

    Domin, B.A., Grill, S.P. and Cheng, Y.-C., Cancer Res43, 2155–2158, 1983.

  16. 16.

    Holmes, D.S. and Bonner, J., Biochem12, 2330–2338, 1973.

  17. 17.

    Zimmerman, S.-B. and Sandeen, G., Anal Biochem14, 267–277, 1966.

  18. 18.

    Aviv, H. and Leder, P., Proc Natl Acad Sci USA69, 1408–1411, 1972.

  19. 19.

    Thomas, P.S., Proc Natl Acad Sci USA77, 5201–5205, 1980.

  20. 20.

    Wang, S.-Y., La Rosa, G.J. and Gudas, L.J., Dev Biol107, 75–86, 1985.

  21. 21.

    McKnight, G.S. and Palmiter, R.D., J Biol Chem254, 9050–9058, 1979.

  22. 22.

    Will, C.L. and Dolnick, B.J., Mol Pharmacol29, 135–148, 1986.

  23. 23.

    Yager, D.R. and Bachenheimer, S.L., Virus Genes1, 135–148, 1988.

  24. 24.

    Kemp, L.M. and Latchman, D.S., Virol166, 258–261. 1988.

  25. 25.

    Mayman, B.A. and Nishioka, Y., J Virol53, 1–6, 1985.

  26. 26.

    Fenwick, M.L. and Clark, J., J Gen Virol61, 121–125, 1983.

  27. 27.

    Biswal, N., Felden, P. and Levy, C.C., Biochim Biophys Acta40, 379–389, 1983.

  28. 28.

    Leary, K. and Franke, B., J Gen Virol65, 1341–1350, 1984.

  29. 29.

    Mullier, M.T., Bolles, C.S. and Parris, D.S., J Gen Virol66, 1565–1574, 1985.

  30. 30.

    Bapat, A.R., Han, F.-S., Liu, Z., Zhou, B.-S.,and Cheng, Y.-C., J Gen Virol68, 2231–2237, 1987.

  31. 31.

    Frink, R.J., Anderson, K.P. and Wagner, E.K., J Virol39, 559–572, 1981.

  32. 32.

    Zhang, Y.-F. and Wagner, E.K., Virus Genes1, 49–60, 1987.

  33. 33.

    Morandi, G.J., Masters, J., Mottes, M. and Attardi, G., J Mol Biol156, 583–607, 1982.

  34. 34.

    Brawerman, G., Cell48, 5–6, 1987.

  35. 35.

    Lüscher, B., Stauber, C., Schindler, R. and Schumperli, D., Proc Natl Acad Sci USA82, 4389–4393, 1985.

  36. 36.

    Cayley, J., Davies, J.A., McCullaugh, K.G. and Kerr, I.M., Eur J Biochem143, 165–174, 1984.

  37. 37.

    Bonven, B.J., Gocke, E. and Westergaard, O., Cell41, 541–551, 1985.

  38. 38.

    Minden, J.S. and Mariens, K.J., J Biol Chem260, 9316–9325, 1985.

  39. 39.

    Jongoneel, C.V. and Bachenheimer, S.L., J Virol39, 656–660, 1981.

Download references

Author information

Correspondence to Yung-Chi Cheng.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bastow, K.F., Zhou, B. & Cheng, Y. Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function. Virus Genes 2, 357–365 (1989). https://doi.org/10.1007/BF00684043

Download citation

Key words

  • human topoisomerase messenger RNA
  • herpes simplex virus type 2
  • rapid messenger RNA degradation
  • susceptibility to shut-off function